EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of Cryopreservation

Genqiao Jiang, Brigitte Neuber, Angela Hückelhoven-Krauss, Uta E Höpken, Yuntian Ding, David Sedloev, Lei Wang, Avinoam Reichman, Franziska Eberhardt, Martin Wermke, Armin Rehm, Carsten Müller-Tidow und 2 weitere

International Journal of Molecular Sciences · 23.01.2024 · 25 (3) · 1394

DOI: 10.3390/ijms25031394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.01.2024. Verfasst von Genqiao Jiang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine V, University Clinic Heidelberg, 69120 Heidelberg, Germany. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Multiple Myeloma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Cancer Research Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The search for target antigens for CAR-T cell therapy against multiple myeloma defined the B-cell maturation antigen (BCMA) as an interesting candidate. Several studies with BCMA-directed CAR-T cell therapy showed promising results. Second-generation point-of-care BCMA.CAR-T cells were manufactured to be of a GMP (good manufacturing practice) standard using the CliniMACS Prodigy® device. Cytokine release in BCMA.CAR-T cells after stimulation with BCMA positive versus negative myeloma cell lines, U266/HL60, was assessed via intracellular staining and flow cytometry. The short-term cytotoxic potency of CAR-T cells was evaluated by chromium-51 release, while the long-term potency used co-culture (3 days/round) at effector/target cell ratios of 1:1 and 1:4. To evaluate the activation and exhaustion of CAR-T cells, exhaustion markers were assessed via flow cytometry. Stability was tested through a comparison of these evaluations at different timepoints: d0 as well as d + 14, d + 90 and d + 365 of cryopreservation. As results, (1) Killing efficiency of U266 cells correlated with the dose of CAR-T cells in a classical 4 h chromium-release assay. There was no significant difference after cryopreservation on different timepoints. (2) In terms of endurance of BCMA.CAR-T cell function, BCMA.CAR-T cells kept their ability to kill all tumor cells over six rounds of co-culture. (3) BCMA.CAR-T cells released high amounts of cytokines upon stimulation with tumor cells. There was no significant difference in cytokine release after cryopreservation. According to the results, BCMA.CAR-T cells manufactured under GMP conditions exerted robust and specific killing of target tumor cells with a high release of cytokines. Even after 1 year of cryopreservation, cytotoxic functions were maintained at the same level. This gives clinicians sufficient time to adjust the timepoint of BCMA.CAR-T cell application to the patient’s course of the underlying disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenMultiple MyelomaHumansB-Cell Maturation AntigenPoint-of-Care SystemsImmunotherapy, AdoptiveCytokinesT-LymphocytesCryopreservation

Stichwörter der Autor:innen

B-cell maturation antigen (BCMA)CAR-T cellsmultiple myelomastability and function of CAR-T cellstimepoint

Substanzen

Receptors, Chimeric AntigenB-Cell Maturation AntigenCytokines

Autor:innen und Institutionen

  • Department of Internal Medicine V, University Clinic Heidelberg, 69120 Heidelberg, Germany.
  • Department of Translational Tumor Immunology, Max-Delbrück Center for Molecular Medicine (MDC), 13125 Berlin, Germany.
  • Early Clinical Trial Unit (ECTU), Medical Clinic and Poliklinik I, Carl Gustav Carus University, 01307 Dresden, Germany.

ORCID-Profile: Michael Schmitt

Förderung

  • German Cancer Research Center

Zitieren

APA

Jiang, G., Neuber, B., Hückelhoven-Krauss, A., Höpken, U. E., Ding, Y., Sedloev, D., Wang, L., Reichman, A., Eberhardt, F., Wermke, M., Rehm, A., Müller-Tidow, C., Schmitt, A., & Schmitt, M. (2024). In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of Cryopreservation. International Journal of Molecular Sciences, 25(3), 1394. https://doi.org/10.3390/ijms25031394

Vancouver

Jiang G, Neuber B, Hückelhoven-Krauss A, Höpken UE, Ding Y, Sedloev D, et al. In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of Cryopreservation. International Journal of Molecular Sciences. 2024;25(3):1394. doi:10.3390/ijms25031394

BibTeX
@article{Jiang2024,
  author = {Jiang, Genqiao and Neuber, Brigitte and Hückelhoven-Krauss, Angela and Höpken, Uta E and Ding, Yuntian and Sedloev, David and Wang, Lei and Reichman, Avinoam and Eberhardt, Franziska and Wermke, Martin and Rehm, Armin and Müller-Tidow, Carsten and Schmitt, Anita and Schmitt, Michael},
  title = {In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of Cryopreservation},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {3},
  pages = {1394},
  doi = {10.3390/ijms25031394}
}
Kostenlos starten →